These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 2236509

  • 21. Metabolism and radiosensitization of 4,5-dimethylmisonidazole, a ring-substituted analog of misonidazole.
    Born JL, Smith BR, Harper N, Koch CJ.
    Biochem Pharmacol; 1992 Mar 17; 43(6):1337-44. PubMed ID: 1562284
    [Abstract] [Full Text] [Related]

  • 22. Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908.
    Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliott W, Suto M, Sebolt-Leopold J.
    Int J Radiat Oncol Biol Phys; 1992 Mar 17; 22(3):545-8. PubMed ID: 1735694
    [Abstract] [Full Text] [Related]

  • 23. The phosphate-group of DNA as a potential target for RSU-1069, a nitroimidazole-aziridine radiosensitizer.
    Silver AR, O'Neill P, Jenkins TC, McNeil SS.
    Int J Radiat Oncol Biol Phys; 1986 Jul 17; 12(7):1203-6. PubMed ID: 3755715
    [Abstract] [Full Text] [Related]

  • 24. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.
    Stratford IJ, Walling JM, Silver AR.
    Br J Cancer; 1986 Mar 17; 53(3):339-44. PubMed ID: 3754453
    [Abstract] [Full Text] [Related]

  • 25. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
    Hill RP, Gulyas S, Whitmore GF.
    Br J Cancer; 1986 Jun 17; 53(6):743-51. PubMed ID: 3755053
    [Abstract] [Full Text] [Related]

  • 26. In vitro cytotoxicity and chemosensitizing activity of the dual function nitroimidazole RB 6145.
    Siemann DW.
    Int J Radiat Oncol Biol Phys; 1994 May 15; 29(2):301-6. PubMed ID: 8195023
    [Abstract] [Full Text] [Related]

  • 27. RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions.
    Stratford IJ, O'Neill P, Sheldon PW, Silver AR, Walling JM, Adams GE.
    Biochem Pharmacol; 1986 Jan 01; 35(1):105-9. PubMed ID: 3753579
    [No Abstract] [Full Text] [Related]

  • 28. A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.
    Suto MJ, Stier MA, Werbel LM, Arundel-Suto CM, Leopold WR, Elliott WE, Sebolt-Leopold JS.
    J Med Chem; 1991 Aug 01; 34(8):2484-8. PubMed ID: 1875345
    [Abstract] [Full Text] [Related]

  • 29. Enhancement of DNA damage in mammalian cells upon bioreduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131.
    Jenner TJ, Sapora O, O'Neill P, Fielden EM.
    Biochem Pharmacol; 1988 Oct 15; 37(20):3837-42. PubMed ID: 3190731
    [Abstract] [Full Text] [Related]

  • 30. Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069.
    Siemann DW, Alliet K, Maddison K, Wolf K.
    Cancer Treat Rep; 1985 Dec 15; 69(12):1409-14. PubMed ID: 3841024
    [Abstract] [Full Text] [Related]

  • 31. Photosensitive interaction of RSU 1069 with DNA.
    Edwards DI, Knox RJ, Skolimowski IM, Zahoor A, Knight RC.
    Int J Radiat Oncol Biol Phys; 1984 Aug 15; 10(8):1319-22. PubMed ID: 6547937
    [Abstract] [Full Text] [Related]

  • 32. Assessment of the repair and damage of DNA induced by parent and reduced RSU-1069, a 2-nitroimidazole-aziridine.
    O'Neill P, Cunniffe SM.
    Int J Radiat Oncol Biol Phys; 1989 Apr 15; 16(4):963-6. PubMed ID: 2649467
    [Abstract] [Full Text] [Related]

  • 33. The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model.
    Siemann DW.
    Int J Radiat Oncol Biol Phys; 1989 Apr 15; 16(4):1115-8. PubMed ID: 2703392
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
    Walton MI, Workman P.
    Cancer Chemother Pharmacol; 1988 Apr 15; 22(4):275-81. PubMed ID: 3168141
    [Abstract] [Full Text] [Related]

  • 35. Oncogenic transforming potential of etanidazole.
    Hall EJ, Hei TK.
    Int J Radiat Oncol Biol Phys; 1992 Apr 15; 22(4):743-5. PubMed ID: 1531978
    [Abstract] [Full Text] [Related]

  • 36. Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069.
    Workman P, Walton MI.
    Int J Radiat Oncol Biol Phys; 1984 Aug 15; 10(8):1307-10. PubMed ID: 6547936
    [Abstract] [Full Text] [Related]

  • 37. Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins.
    Jenkins TC, Naylor MA, O'Neill P, Threadgill MD, Cole S, Stratford IJ, Adams GE, Fielden EM, Suto MJ, Stier MA.
    J Med Chem; 1990 Sep 15; 33(9):2603-10. PubMed ID: 2391699
    [Abstract] [Full Text] [Related]

  • 38. Induction of DNA crosslinks in vitro upon reduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131.
    O'Neill P, McNeil SS, Jenkins TC.
    Biochem Pharmacol; 1987 Jun 01; 36(11):1787-92. PubMed ID: 3579973
    [Abstract] [Full Text] [Related]

  • 39. Oncogenic transformation in vitro by the hypoxic cell sensitizer misonidazole.
    Miller RC, Hall EJ.
    Br J Cancer; 1978 Sep 01; 38(3):411-7. PubMed ID: 708572
    [Abstract] [Full Text] [Related]

  • 40. High uptake of RSU 1069 and its analogues melanotic melanomas.
    Walling JM, Deacon J, Holliday S, Stratford IJ.
    Cancer Chemother Pharmacol; 1989 Sep 01; 24(1):28-32. PubMed ID: 2541936
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.